Terms: = Head and neck cancer AND LMNA, EMD2, 4000, ENSG00000160789, LGMD1B, LDP1, PRO1, LMNC, FPLD, CDDC, HGPS, P02545, LFP, IDC, CMD1A, CDCD1, LMN1, CMT2B1, FPL AND Treatment
119 results:
1. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
Riedmeier M; Antonini SRR; Brandalise S; Costa TEJB; Daiggi CM; de Figueiredo BC; de Krijger RR; De Sá Rodrigues KE; Deal C; Del Rivero J; Engstler G; Fassnacht M; Fernandes Luiz Canali GC; Molina CAF; Gonc EN; Gültekin M; Haak HR; Guran T; Hendriks Allaird EJ; Idkowiak J; Kuhlen M; Malkin D; Meena JP; Pamporaki C; Pinto E; Puglisi S; Ribeiro RC; Thompson LDR; Yalcin B; Van Noesel M; Wiegering V
Eur J Endocrinol; 2024 Mar; 190(4):G15-G24. PubMed ID: 38552173
[TBL] [Abstract] [Full Text] [Related]
2. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Chen QY; Guo SS; Luo Y; Qu S; Wu DH; Chen XZ; Chen DP; Qin XT; Lin Q; Jin F; Lin SJ; Yao ZF; Liu W; Maxwell Wang Z; Li BY; Xia M; Xu RH; Tang LQ; Mai HQ
Oral Oncol; 2024 Apr; 151():106723. PubMed ID: 38387261
[TBL] [Abstract] [Full Text] [Related]
4. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
Guo SS; Yang JH; Sun XS; Liu LZ; Yang ZC; Liu LT; Liu SL; Li XY; Lv XF; Luo DH; Li JB; Liu Q; Wang P; Guo L; Mo HY; Sun R; Yang Q; Liang YJ; Jia GD; Zhao C; Chen QY; Tang LQ; Mai HQ
Eur J Cancer; 2023 Nov; 194():113336. PubMed ID: 37801967
[TBL] [Abstract] [Full Text] [Related]
5. Concurrent chemoradiotherapy with or without neoadjuvant chemotherapy in pediatric patients with stage III-IVa nasopharyngeal carcinoma: a real-world propensity score-matched cohort study.
Jin YN; Ruan ZH; Cao WW; Yang L; Yao W; Pei XF; Zhang WJ; Marks T; Yao JJ; Xia LP
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11929-11940. PubMed ID: 37418058
[TBL] [Abstract] [Full Text] [Related]
6. Determinants of bone parameters in young paediatric cancer survivors: the iBoneFIT project.
Marmol-Perez A; Ubago-Guisado E; Llorente-Cantarero FJ; Vlachopoulos D; Rodriguez-Solana A; Gil-Cosano JJ; Ruiz JR; Gracia-Marco L
Pediatr Res; 2023 Oct; 94(4):1538-1546. PubMed ID: 37202528
[TBL] [Abstract] [Full Text] [Related]
7. A universal approach for synthesis of copper nanoclusters templated by G-rich oligonucleotide sequences and their applications in sensing.
Liu H; Yang X; Huang B; Liu H
Spectrochim Acta A Mol Biomol Spectrosc; 2023 Sep; 297():122740. PubMed ID: 37080047
[TBL] [Abstract] [Full Text] [Related]
8. Intraductal Carcinoma: The Carcinoma In Situ of the Salivary Gland.
Thomas R; Umar T; Borumandi F
J Craniofac Surg; 2023 Jul-Aug 01; 34(5):e432-e434. PubMed ID: 37011225
[TBL] [Abstract] [Full Text] [Related]
9. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission?
Mao JR; Lan KQ; Liu SL; Liu C; Xie SY; Li SC; Ye WF; Sun XS; Mai HQ
Radiother Oncol; 2023 Feb; 179():109445. PubMed ID: 36566987
[TBL] [Abstract] [Full Text] [Related]
10. Oral cancer screening prevalence in low-income adults before and after the ACA.
Semprini J
Oral Oncol; 2022 Nov; 134():106055. PubMed ID: 36029746
[TBL] [Abstract] [Full Text] [Related]
11. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract] [Full Text] [Related]
12. Palliation of head and neck cancer: a review of the unique difficulties.
Weaver A; Smith M; Wilson S; Douglas CM; Montgomery J; Finlay F
Int J Palliat Nurs; 2022 Jul; 28(7):333-341. PubMed ID: 35861441
[TBL] [Abstract] [Full Text] [Related]
13. Effect of age on resting energy expenditure in patients with cancer.
de Souza MTP; Ozorio GA; de Oliveira GN; López RVM; Alves-Almeida MMF; Kulcsar MAV; Ribeiro U; Singer P; Waitzberg DL
Nutrition; 2022 Oct; 102():111740. PubMed ID: 35843100
[TBL] [Abstract] [Full Text] [Related]
14. Prospective Evaluation of Taste Function in Patients With head and neck cancer Receiving Intensity-Modulated Radiotherapy.
Chen WC; Hsu CM; Tsai YT; Lin MH; Tsai MS; Chang GH; Lai CH; Fang F; Chen MF
JAMA Otolaryngol Head Neck Surg; 2022 Jul; 148(7):604-611. PubMed ID: 35616981
[TBL] [Abstract] [Full Text] [Related]
15. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial.
Tang SQ; Chen L; Li WF; Chan ATC; Huang SH; Chua MLK; O'Sullivan B; Lee AWM; Lee NY; Zhang Y; Chen YP; Xu C; Sun Y; Tang LL; Ma J
Radiother Oncol; 2022 Feb; 167():179-186. PubMed ID: 34971660
[TBL] [Abstract] [Full Text] [Related]
16. Induction or adjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in paediatric nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA.
Liang YJ; Wen DX; Luo MJ; Tang LQ; Guo SS; Wang P; Chen QY; Liu LT; Mai HQ
Eur J Cancer; 2021 Dec; 159():133-143. PubMed ID: 34743068
[TBL] [Abstract] [Full Text] [Related]
17. Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.
Liu LT; Liang YJ; Guo SS; Xie Y; Jia GD; Wen DX; Tang LQ; Chen QY; Mai HQ
Head Neck; 2022 Jan; 44(1):34-45. PubMed ID: 34636116
[TBL] [Abstract] [Full Text] [Related]
18. Does three cycles of neoadjuvant chemotherapy prior to concurrent chemoradiotherapy provide benefits for all childhood patients with locoregionally advanced nasopharyngeal carcinoma?
Jin YN; Cao HJ; Gong XH; Zhang WJ; Marks T; Yao JJ; Xia LP
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2569-2579. PubMed ID: 34618220
[TBL] [Abstract] [Full Text] [Related]
19. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract] [Full Text] [Related]
20. Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes.
Meijers A; Guterres Marmitt G; Ng Wei Siang K; van der Schaaf A; Knopf AC; Langendijk JA; Both S
Radiother Oncol; 2020 Sep; 150():136-141. PubMed ID: 32579999
[TBL] [Abstract] [Full Text] [Related]
[Next]
